Evidence map›Paper›PMID 40387277›Full record

ArticleAmerican journal of hematology2025

Routine Screening of Strongyloides Among Patients With Lymphoma and Efficacy of Targeted Prophylaxis.

Michele D Stanchina, Camila Sacher, Yamila Melendez, Pamela Dudkiewicz, Jose F Camargo, Izidore S Lossos

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michele D StanchinaDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Camila SacherUniversity of Miami, Leonard M. Miller School of Medicine, Miami, Florida, USA.
Yamila MelendezDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Pamela DudkiewiczDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Jose F CamargoDivision of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Izidore S LossosDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.ORCID 0000-0002-9346-9013

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCLR01CA233945 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S, VERDUN, RAMIRO ERNESTO · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA233945
6 · The paper itself

Abstract

A total of 1372 lymphoma patients (980 newly diagnosed and 392 seen in cellular therapy clinic) were screened for Strongyloides serology, detecting IgG in 80 (6%) patients. Only one out of 80 (1.25%) patients diagnosed and treated with ivermectin for Strongyloides developed disseminated strongyloidiasis following chemotherapy treatments, supporting routine screening and prophylaxis in lymphoma patients.

Indexed as

IvermectinLymphomaStrongyloidesStrongyloidiasisAdultAgedAged, 80 and overAnimalsAntibodies, HelminthFemaleHumansImmunoglobulin GMaleMass ScreeningMiddle AgedAntibodies, HelminthImmunoglobulin GIvermectinlymphomaprophylaxisStrongyloides

Identifiers

PMID40387277
PMCPMC12234232

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.